- MasterPharm LLC
New Jersey District
July 7, 2017
Stephen S. Laddy, CEO
11502 Liberty Ave, 2nd Floor
South Richmond Hill, NY 11419-1902
Dear Mr. Laddy:
The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter [WL #: NYK-2016-18] dated January 8, 2016. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.
You are expected to take all necessary steps to assure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
New Jersey District Office
Office of Regulatory Affairs
U.S. Food and Drug Administration